A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-10

AUTHORS

Bernard Escudier, Sandrine Faivre, Eric Van Cutsem, Nathalie Germann, Jean-Christophe Pouget, Ruth Plummer, Ignace Vergote, Fiona Thistlethwaite, Georg A. Bjarnason, Robert Jones, Helen Mackay, Julien Edeline, Laetitia Fartoux, Hal Hirte, Amit Oza

ABSTRACT

BACKGROUND: Tasquinimod is a small molecule with immunomodulatory, anti-angiogenic, and anti-metastatic properties that targets the tumor microenvironment. This study aimed to obtain a clinical proof of concept that tasquinimod was active and tolerable in patients with advanced solid tumors. PATIENTS AND METHODS: This early stopping design, open-label, proof-of-concept clinical trial evaluated the clinical activity of tasquinimod in four independent cohorts of patients with advanced hepatocellular (n = 53), ovarian (n = 55), renal cell (n = 38), and gastric (n = 21) cancers. Tasquinimod was given orally every day (0.5 mg/day for at least 2 weeks, with dose increase to 1 mg/day) until radiological progression according to Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 criteria, intolerable toxicity, or patient withdrawal. The primary efficacy endpoint was progression-free survival (PFS) rate according to RECIST 1.1 by central assessment. RESULTS: Interim futility analyses at 8 weeks (6 weeks for the gastric cancer cohort) found adequate clinical activity of tasquinimod only in the hepatocellular cohort and recruitment to the other three cohorts was stopped. PFS rates were 26.9% at 16 weeks, 7.3% at 24 weeks, 13.2% at 16 weeks, and 9.5% at 12 weeks, respectively, in hepatocellular, ovarian, renal cell, and gastric cancer cohorts. The pre-defined PFS threshold was not reached in the hepatocellular cancer cohort at the second stage of the trial. The most common treatment-related adverse events were fatigue (48.5%), nausea (34.1%), decreased appetite (31.7%), and vomiting (24.6%). CONCLUSIONS: This study failed to demonstrate clinical activity of tasquinimod in heavily pre-treated patients with advanced hepatocellular, ovarian, renal cell, and gastric cancer. TRIAL REGISTRATION: NCT01743469. More... »

PAGES

655-661

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11523-017-0525-2

DOI

http://dx.doi.org/10.1007/s11523-017-0525-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1091144471

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28798986


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ovarian Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quinolones", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Stomach Neoplasms", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Oncology Department, Gustave-Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Escudier", 
        "givenName": "Bernard", 
        "id": "sg:person.01304252172.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304252172.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "H\u00f4pitaux Universitaires Paris Nord Val de Seine (HUPVNS), Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Faivre", 
        "givenName": "Sandrine", 
        "id": "sg:person.01026352014.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026352014.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universitaire Ziekenhuizen Leuven", 
          "id": "https://www.grid.ac/institutes/grid.410569.f", 
          "name": [
            "University Hospitals Gasthuisberg and KULeuven, Leuven, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Van Cutsem", 
        "givenName": "Eric", 
        "id": "sg:person.01214007230.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214007230.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ipsen (France)", 
          "id": "https://www.grid.ac/institutes/grid.476474.2", 
          "name": [
            "Ipsen Innovation, Les Ulis, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Germann", 
        "givenName": "Nathalie", 
        "id": "sg:person.012632134127.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012632134127.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ipsen (France)", 
          "id": "https://www.grid.ac/institutes/grid.476474.2", 
          "name": [
            "Ipsen Innovation, Les Ulis, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pouget", 
        "givenName": "Jean-Christophe", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Freeman Hospital", 
          "id": "https://www.grid.ac/institutes/grid.415050.5", 
          "name": [
            "Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Plummer", 
        "givenName": "Ruth", 
        "id": "sg:person.01360307700.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01360307700.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universitaire Ziekenhuizen Leuven", 
          "id": "https://www.grid.ac/institutes/grid.410569.f", 
          "name": [
            "University Hospitals Gasthuisberg and KULeuven, Leuven, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vergote", 
        "givenName": "Ignace", 
        "id": "sg:person.0706143575.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706143575.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Christie Hospital NHS Foundation Trust", 
          "id": "https://www.grid.ac/institutes/grid.412917.8", 
          "name": [
            "The Christie NHS Foundation Trust, Manchester, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thistlethwaite", 
        "givenName": "Fiona", 
        "id": "sg:person.0720275643.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720275643.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sunnybrook Health Science Centre", 
          "id": "https://www.grid.ac/institutes/grid.413104.3", 
          "name": [
            "Sunnybrook Odette Cancer Centre, Toronto, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bjarnason", 
        "givenName": "Georg A.", 
        "id": "sg:person.011011560677.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011011560677.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Glasgow", 
          "id": "https://www.grid.ac/institutes/grid.8756.c", 
          "name": [
            "Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jones", 
        "givenName": "Robert", 
        "id": "sg:person.0737650202.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0737650202.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sunnybrook Health Science Centre", 
          "id": "https://www.grid.ac/institutes/grid.413104.3", 
          "name": [
            "Sunnybrook Odette Cancer Centre, Toronto, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mackay", 
        "givenName": "Helen", 
        "id": "sg:person.0671632453.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671632453.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Eug\u00e8ne Marquis", 
          "id": "https://www.grid.ac/institutes/grid.417988.b", 
          "name": [
            "Centre Eug\u00e8ne Marquis, Rennes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Edeline", 
        "givenName": "Julien", 
        "id": "sg:person.0657306623.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0657306623.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Saint-Antoine", 
          "id": "https://www.grid.ac/institutes/grid.412370.3", 
          "name": [
            "Saint-Antoine University Hospital, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fartoux", 
        "givenName": "Laetitia", 
        "id": "sg:person.01244411011.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01244411011.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "McMaster University", 
          "id": "https://www.grid.ac/institutes/grid.25073.33", 
          "name": [
            "Juravinski Cancer Centre, McMaster University, Hamilton, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hirte", 
        "givenName": "Hal", 
        "id": "sg:person.015413523347.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015413523347.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Glasgow", 
          "id": "https://www.grid.ac/institutes/grid.8756.c", 
          "name": [
            "Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Oza", 
        "givenName": "Amit", 
        "id": "sg:person.01306134155.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306134155.52"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2011.35.6295", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000373548"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s40425-015-0098-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005098127", 
          "https://doi.org/10.1186/s40425-015-0098-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s40425-015-0098-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005098127", 
          "https://doi.org/10.1186/s40425-015-0098-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-013-2321-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007320327", 
          "https://doi.org/10.1007/s00280-013-2321-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-013-2321-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007320327", 
          "https://doi.org/10.1007/s00280-013-2321-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc2442", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013847179", 
          "https://doi.org/10.1038/nrc2442"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/sim.2866", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014885375"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2016.66.9697", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021704942"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2008.10.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026558254"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cco.0000000000000110", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027537471"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cco.0000000000000110", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027537471"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc2444", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034686698", 
          "https://doi.org/10.1038/nrc2444"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0034207", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037781605"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/2326-6066.cir-14-0036", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038322758"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdx487", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092263093"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-10", 
    "datePublishedReg": "2017-10-01", 
    "description": "BACKGROUND: Tasquinimod is a small molecule with immunomodulatory, anti-angiogenic, and anti-metastatic properties that targets the tumor microenvironment. This study aimed to obtain a clinical proof of concept that tasquinimod was active and tolerable in patients with advanced solid tumors.\nPATIENTS AND METHODS: This early stopping design, open-label, proof-of-concept clinical trial evaluated the clinical activity of tasquinimod in four independent cohorts of patients with advanced hepatocellular (n\u00a0=\u00a053), ovarian (n\u00a0=\u00a055), renal cell (n\u00a0=\u00a038), and gastric (n\u00a0=\u00a021) cancers. Tasquinimod was given orally every day (0.5\u00a0mg/day for at least 2\u00a0weeks, with dose increase to 1\u00a0mg/day) until radiological progression according to Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 criteria, intolerable toxicity, or patient withdrawal. The primary efficacy endpoint was progression-free survival (PFS) rate according to RECIST 1.1 by central assessment.\nRESULTS: Interim futility analyses at 8\u00a0weeks (6\u00a0weeks for the gastric cancer cohort) found adequate clinical activity of tasquinimod only in the hepatocellular cohort and recruitment to the other three cohorts was stopped. PFS rates were 26.9% at 16\u00a0weeks, 7.3% at 24\u00a0weeks, 13.2% at 16\u00a0weeks, and 9.5% at 12\u00a0weeks, respectively, in hepatocellular, ovarian, renal cell, and gastric cancer cohorts. The pre-defined PFS threshold was not reached in the hepatocellular cancer cohort at the second stage of the trial. The most common treatment-related adverse events were fatigue (48.5%), nausea (34.1%), decreased appetite (31.7%), and vomiting (24.6%).\nCONCLUSIONS: This study failed to demonstrate clinical activity of tasquinimod in heavily pre-treated patients with advanced hepatocellular, ovarian, renal cell, and gastric cancer.\nTRIAL REGISTRATION: NCT01743469.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s11523-017-0525-2", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1036678", 
        "issn": [
          "1776-2596", 
          "1776-260X"
        ], 
        "name": "Targeted Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "12"
      }
    ], 
    "name": "A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers", 
    "pagination": "655-661", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "d5c112a03559cb5c896c417cde0784ef12c7d28765617d7eae135871292d45c7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28798986"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101270595"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11523-017-0525-2"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1091144471"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11523-017-0525-2", 
      "https://app.dimensions.ai/details/publication/pub.1091144471"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000348_0000000348/records_54338_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs11523-017-0525-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11523-017-0525-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11523-017-0525-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11523-017-0525-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11523-017-0525-2'


 

This table displays all metadata directly associated to this object as RDF triples.

283 TRIPLES      21 PREDICATES      53 URIs      33 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11523-017-0525-2 schema:about N04f9aab50c1b43f5be7e408947e8c18d
2 N0cf39c7c36b8421794eb8faa36769c8e
3 N12961ece34a34c9e9da18703509dbe46
4 N1f1b4b4d820b4b19971d89aaf1a816d1
5 N2a7a9fe24b8d46cc95ab9ece3c79a521
6 N2c18dde54627471f8d029d9f38c6ff37
7 N6d6ae1e8eb654966b1aeba125afda4ab
8 N90602448ed9b4f2c87d521333ecf28ce
9 Na1020553b09849faafde9819f24ee76a
10 Na6d92f5ebc294ca48533e0cf1f678d9d
11 Nb77a7d2bc87c42dd81c4625c5fda2803
12 Nc89427008265477eaa42251c6905b616
13 anzsrc-for:11
14 anzsrc-for:1112
15 schema:author N17d3f3b86d104fc6951f7309ca51ad4d
16 schema:citation sg:pub.10.1007/s00280-013-2321-8
17 sg:pub.10.1038/nrc2442
18 sg:pub.10.1038/nrc2444
19 sg:pub.10.1186/s40425-015-0098-5
20 https://doi.org/10.1002/sim.2866
21 https://doi.org/10.1016/j.ejca.2008.10.026
22 https://doi.org/10.1093/annonc/mdx487
23 https://doi.org/10.1097/cco.0000000000000110
24 https://doi.org/10.1158/2326-6066.cir-14-0036
25 https://doi.org/10.1200/jco.2011.35.6295
26 https://doi.org/10.1200/jco.2016.66.9697
27 https://doi.org/10.1371/journal.pone.0034207
28 schema:datePublished 2017-10
29 schema:datePublishedReg 2017-10-01
30 schema:description BACKGROUND: Tasquinimod is a small molecule with immunomodulatory, anti-angiogenic, and anti-metastatic properties that targets the tumor microenvironment. This study aimed to obtain a clinical proof of concept that tasquinimod was active and tolerable in patients with advanced solid tumors. PATIENTS AND METHODS: This early stopping design, open-label, proof-of-concept clinical trial evaluated the clinical activity of tasquinimod in four independent cohorts of patients with advanced hepatocellular (n = 53), ovarian (n = 55), renal cell (n = 38), and gastric (n = 21) cancers. Tasquinimod was given orally every day (0.5 mg/day for at least 2 weeks, with dose increase to 1 mg/day) until radiological progression according to Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 criteria, intolerable toxicity, or patient withdrawal. The primary efficacy endpoint was progression-free survival (PFS) rate according to RECIST 1.1 by central assessment. RESULTS: Interim futility analyses at 8 weeks (6 weeks for the gastric cancer cohort) found adequate clinical activity of tasquinimod only in the hepatocellular cohort and recruitment to the other three cohorts was stopped. PFS rates were 26.9% at 16 weeks, 7.3% at 24 weeks, 13.2% at 16 weeks, and 9.5% at 12 weeks, respectively, in hepatocellular, ovarian, renal cell, and gastric cancer cohorts. The pre-defined PFS threshold was not reached in the hepatocellular cancer cohort at the second stage of the trial. The most common treatment-related adverse events were fatigue (48.5%), nausea (34.1%), decreased appetite (31.7%), and vomiting (24.6%). CONCLUSIONS: This study failed to demonstrate clinical activity of tasquinimod in heavily pre-treated patients with advanced hepatocellular, ovarian, renal cell, and gastric cancer. TRIAL REGISTRATION: NCT01743469.
31 schema:genre research_article
32 schema:inLanguage en
33 schema:isAccessibleForFree true
34 schema:isPartOf N9bdb34ffc38240ceba17fde2ac54d736
35 Nb41d867509e645879824f64286c2a359
36 sg:journal.1036678
37 schema:name A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers
38 schema:pagination 655-661
39 schema:productId N115befdeef0446ffadcc5965e961938b
40 N160c616c09444c94982c0449194058a3
41 N5fabcd4d42874f56851a920df2a651cb
42 N8836d9921a0c4e10814fb09e8ca1345a
43 N9a4fb81cede04fc0a7df08b8dbaf62f4
44 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091144471
45 https://doi.org/10.1007/s11523-017-0525-2
46 schema:sdDatePublished 2019-04-11T10:22
47 schema:sdLicense https://scigraph.springernature.com/explorer/license/
48 schema:sdPublisher N93165dfd4e124a059c145f410baa845d
49 schema:url https://link.springer.com/10.1007%2Fs11523-017-0525-2
50 sgo:license sg:explorer/license/
51 sgo:sdDataset articles
52 rdf:type schema:ScholarlyArticle
53 N04f9aab50c1b43f5be7e408947e8c18d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
54 schema:name Stomach Neoplasms
55 rdf:type schema:DefinedTerm
56 N0ceaf045b9f6489fb252f20dd8257c60 rdf:first N8f134076a2e44c9b97d0189ee28a3fb0
57 rdf:rest Nf57429d19271450d8a615b7b446826cf
58 N0cf39c7c36b8421794eb8faa36769c8e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
59 schema:name Liver Neoplasms
60 rdf:type schema:DefinedTerm
61 N115befdeef0446ffadcc5965e961938b schema:name nlm_unique_id
62 schema:value 101270595
63 rdf:type schema:PropertyValue
64 N12961ece34a34c9e9da18703509dbe46 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Male
66 rdf:type schema:DefinedTerm
67 N160c616c09444c94982c0449194058a3 schema:name doi
68 schema:value 10.1007/s11523-017-0525-2
69 rdf:type schema:PropertyValue
70 N17d3f3b86d104fc6951f7309ca51ad4d rdf:first sg:person.01304252172.82
71 rdf:rest N2c0948d5b3e94946af80bc98ab78ad9d
72 N1d2dde3d7f274339abe19122be6ba080 schema:name Hôpitaux Universitaires Paris Nord Val de Seine (HUPVNS), Paris, France
73 rdf:type schema:Organization
74 N1f1b4b4d820b4b19971d89aaf1a816d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Carcinoma
76 rdf:type schema:DefinedTerm
77 N2a7a9fe24b8d46cc95ab9ece3c79a521 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Female
79 rdf:type schema:DefinedTerm
80 N2c0948d5b3e94946af80bc98ab78ad9d rdf:first sg:person.01026352014.76
81 rdf:rest Nc6b78962f01b4c17a3406f98e07d3f65
82 N2c18dde54627471f8d029d9f38c6ff37 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Kidney Neoplasms
84 rdf:type schema:DefinedTerm
85 N3032cb3e704b42bf817fabd1545bfdb1 rdf:first sg:person.011011560677.21
86 rdf:rest Nb9c272b1199649d7b6aca645bb6b21f0
87 N3315da56c8b14f68891c651d0d543e42 rdf:first sg:person.0720275643.90
88 rdf:rest N3032cb3e704b42bf817fabd1545bfdb1
89 N37ed7be09c0942fb8c1b68cb7165fe1f rdf:first sg:person.0657306623.46
90 rdf:rest N4fab1cd976164610b7591375f6743820
91 N491dca5b640b4d359eebff9395b38848 rdf:first sg:person.015413523347.78
92 rdf:rest Nfb3706b610904401b686ba811f9dcf46
93 N4fab1cd976164610b7591375f6743820 rdf:first sg:person.01244411011.79
94 rdf:rest N491dca5b640b4d359eebff9395b38848
95 N5fabcd4d42874f56851a920df2a651cb schema:name dimensions_id
96 schema:value pub.1091144471
97 rdf:type schema:PropertyValue
98 N6d6ae1e8eb654966b1aeba125afda4ab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Ovarian Neoplasms
100 rdf:type schema:DefinedTerm
101 N8836d9921a0c4e10814fb09e8ca1345a schema:name readcube_id
102 schema:value d5c112a03559cb5c896c417cde0784ef12c7d28765617d7eae135871292d45c7
103 rdf:type schema:PropertyValue
104 N895e1fe540af48a5865cb3feebfe4273 rdf:first sg:person.0706143575.32
105 rdf:rest N3315da56c8b14f68891c651d0d543e42
106 N8f134076a2e44c9b97d0189ee28a3fb0 schema:affiliation https://www.grid.ac/institutes/grid.476474.2
107 schema:familyName Pouget
108 schema:givenName Jean-Christophe
109 rdf:type schema:Person
110 N90602448ed9b4f2c87d521333ecf28ce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Antineoplastic Agents
112 rdf:type schema:DefinedTerm
113 N930b159644be4150865cb473c4ed06c4 rdf:first sg:person.0671632453.29
114 rdf:rest N37ed7be09c0942fb8c1b68cb7165fe1f
115 N93165dfd4e124a059c145f410baa845d schema:name Springer Nature - SN SciGraph project
116 rdf:type schema:Organization
117 N9a4fb81cede04fc0a7df08b8dbaf62f4 schema:name pubmed_id
118 schema:value 28798986
119 rdf:type schema:PropertyValue
120 N9bdb34ffc38240ceba17fde2ac54d736 schema:volumeNumber 12
121 rdf:type schema:PublicationVolume
122 Na1020553b09849faafde9819f24ee76a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Disease-Free Survival
124 rdf:type schema:DefinedTerm
125 Na6d92f5ebc294ca48533e0cf1f678d9d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Humans
127 rdf:type schema:DefinedTerm
128 Nb41d867509e645879824f64286c2a359 schema:issueNumber 5
129 rdf:type schema:PublicationIssue
130 Nb77a7d2bc87c42dd81c4625c5fda2803 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Kaplan-Meier Estimate
132 rdf:type schema:DefinedTerm
133 Nb9c272b1199649d7b6aca645bb6b21f0 rdf:first sg:person.0737650202.16
134 rdf:rest N930b159644be4150865cb473c4ed06c4
135 Nc6b78962f01b4c17a3406f98e07d3f65 rdf:first sg:person.01214007230.69
136 rdf:rest Nec40f01dede446cb979ea53627e287a3
137 Nc89427008265477eaa42251c6905b616 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Quinolones
139 rdf:type schema:DefinedTerm
140 Nec40f01dede446cb979ea53627e287a3 rdf:first sg:person.012632134127.07
141 rdf:rest N0ceaf045b9f6489fb252f20dd8257c60
142 Nf57429d19271450d8a615b7b446826cf rdf:first sg:person.01360307700.03
143 rdf:rest N895e1fe540af48a5865cb3feebfe4273
144 Nfb3706b610904401b686ba811f9dcf46 rdf:first sg:person.01306134155.52
145 rdf:rest rdf:nil
146 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
147 schema:name Medical and Health Sciences
148 rdf:type schema:DefinedTerm
149 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
150 schema:name Oncology and Carcinogenesis
151 rdf:type schema:DefinedTerm
152 sg:journal.1036678 schema:issn 1776-2596
153 1776-260X
154 schema:name Targeted Oncology
155 rdf:type schema:Periodical
156 sg:person.01026352014.76 schema:affiliation N1d2dde3d7f274339abe19122be6ba080
157 schema:familyName Faivre
158 schema:givenName Sandrine
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026352014.76
160 rdf:type schema:Person
161 sg:person.011011560677.21 schema:affiliation https://www.grid.ac/institutes/grid.413104.3
162 schema:familyName Bjarnason
163 schema:givenName Georg A.
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011011560677.21
165 rdf:type schema:Person
166 sg:person.01214007230.69 schema:affiliation https://www.grid.ac/institutes/grid.410569.f
167 schema:familyName Van Cutsem
168 schema:givenName Eric
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214007230.69
170 rdf:type schema:Person
171 sg:person.01244411011.79 schema:affiliation https://www.grid.ac/institutes/grid.412370.3
172 schema:familyName Fartoux
173 schema:givenName Laetitia
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01244411011.79
175 rdf:type schema:Person
176 sg:person.012632134127.07 schema:affiliation https://www.grid.ac/institutes/grid.476474.2
177 schema:familyName Germann
178 schema:givenName Nathalie
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012632134127.07
180 rdf:type schema:Person
181 sg:person.01304252172.82 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
182 schema:familyName Escudier
183 schema:givenName Bernard
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304252172.82
185 rdf:type schema:Person
186 sg:person.01306134155.52 schema:affiliation https://www.grid.ac/institutes/grid.8756.c
187 schema:familyName Oza
188 schema:givenName Amit
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306134155.52
190 rdf:type schema:Person
191 sg:person.01360307700.03 schema:affiliation https://www.grid.ac/institutes/grid.415050.5
192 schema:familyName Plummer
193 schema:givenName Ruth
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01360307700.03
195 rdf:type schema:Person
196 sg:person.015413523347.78 schema:affiliation https://www.grid.ac/institutes/grid.25073.33
197 schema:familyName Hirte
198 schema:givenName Hal
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015413523347.78
200 rdf:type schema:Person
201 sg:person.0657306623.46 schema:affiliation https://www.grid.ac/institutes/grid.417988.b
202 schema:familyName Edeline
203 schema:givenName Julien
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0657306623.46
205 rdf:type schema:Person
206 sg:person.0671632453.29 schema:affiliation https://www.grid.ac/institutes/grid.413104.3
207 schema:familyName Mackay
208 schema:givenName Helen
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671632453.29
210 rdf:type schema:Person
211 sg:person.0706143575.32 schema:affiliation https://www.grid.ac/institutes/grid.410569.f
212 schema:familyName Vergote
213 schema:givenName Ignace
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706143575.32
215 rdf:type schema:Person
216 sg:person.0720275643.90 schema:affiliation https://www.grid.ac/institutes/grid.412917.8
217 schema:familyName Thistlethwaite
218 schema:givenName Fiona
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720275643.90
220 rdf:type schema:Person
221 sg:person.0737650202.16 schema:affiliation https://www.grid.ac/institutes/grid.8756.c
222 schema:familyName Jones
223 schema:givenName Robert
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0737650202.16
225 rdf:type schema:Person
226 sg:pub.10.1007/s00280-013-2321-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007320327
227 https://doi.org/10.1007/s00280-013-2321-8
228 rdf:type schema:CreativeWork
229 sg:pub.10.1038/nrc2442 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013847179
230 https://doi.org/10.1038/nrc2442
231 rdf:type schema:CreativeWork
232 sg:pub.10.1038/nrc2444 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034686698
233 https://doi.org/10.1038/nrc2444
234 rdf:type schema:CreativeWork
235 sg:pub.10.1186/s40425-015-0098-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005098127
236 https://doi.org/10.1186/s40425-015-0098-5
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1002/sim.2866 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014885375
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1016/j.ejca.2008.10.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026558254
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1093/annonc/mdx487 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092263093
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1097/cco.0000000000000110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027537471
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1158/2326-6066.cir-14-0036 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038322758
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1200/jco.2011.35.6295 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000373548
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1200/jco.2016.66.9697 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021704942
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1371/journal.pone.0034207 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037781605
253 rdf:type schema:CreativeWork
254 https://www.grid.ac/institutes/grid.14925.3b schema:alternateName Institut Gustave Roussy
255 schema:name Oncology Department, Gustave-Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France
256 rdf:type schema:Organization
257 https://www.grid.ac/institutes/grid.25073.33 schema:alternateName McMaster University
258 schema:name Juravinski Cancer Centre, McMaster University, Hamilton, Canada
259 rdf:type schema:Organization
260 https://www.grid.ac/institutes/grid.410569.f schema:alternateName Universitaire Ziekenhuizen Leuven
261 schema:name University Hospitals Gasthuisberg and KULeuven, Leuven, Belgium
262 rdf:type schema:Organization
263 https://www.grid.ac/institutes/grid.412370.3 schema:alternateName Hôpital Saint-Antoine
264 schema:name Saint-Antoine University Hospital, Paris, France
265 rdf:type schema:Organization
266 https://www.grid.ac/institutes/grid.412917.8 schema:alternateName Christie Hospital NHS Foundation Trust
267 schema:name The Christie NHS Foundation Trust, Manchester, UK
268 rdf:type schema:Organization
269 https://www.grid.ac/institutes/grid.413104.3 schema:alternateName Sunnybrook Health Science Centre
270 schema:name Sunnybrook Odette Cancer Centre, Toronto, Canada
271 rdf:type schema:Organization
272 https://www.grid.ac/institutes/grid.415050.5 schema:alternateName Freeman Hospital
273 schema:name Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK
274 rdf:type schema:Organization
275 https://www.grid.ac/institutes/grid.417988.b schema:alternateName Centre Eugène Marquis
276 schema:name Centre Eugène Marquis, Rennes, France
277 rdf:type schema:Organization
278 https://www.grid.ac/institutes/grid.476474.2 schema:alternateName Ipsen (France)
279 schema:name Ipsen Innovation, Les Ulis, France
280 rdf:type schema:Organization
281 https://www.grid.ac/institutes/grid.8756.c schema:alternateName University of Glasgow
282 schema:name Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK
283 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...